Abstract
Introduction Sclerosing angiomatoid nodular transformation (SANT) of the spleen is a rare benign vascular lesion with unknown etiopathogenesis and with definite features of imaging, histopathology, and immunohistochemistry. It was first described by Martel et al. in 2004, and to date, only 151 cases have been reported. Case Description We report a case of SANT of the spleen detected in a 66-year-old Caucasian, without comorbidities, presented to our department with epigastric pain. We, also, presented a review of the literature. Conclusions SANT is a benign incidentally vascular condition in the majority of cases. The wide age and gender distribution in our review is in accordance with that in previous studies in English literature. In our opinion, splenectomy is the choice treatment because it is at the same time diagnostic and therapeutic in a definitive way.
Highlights
Sclerosing angiomatoid nodular transformation (SANT) of the spleen is a rare benign vascular lesion with unknown etiopathogenesis and with definite features of imaging, histopathology, and immunohistochemistry
We decided to proceed with surgical therapy, without making a spleen biopsy, and we opted for a laparoscopic splenectomy, because of diagnostic uncertainty due to unspecific features of imaging not excluding the malignant lesion nature
The immunohistochemical stains for HHV8, EBV-LMP1, and ALK1 were negative. All these features were consistent with sclerosing angiomatoid nodular transformation of the spleen
Summary
Sclerosing angiomatoid nodular transformation (SANT) of the spleen is a rare benign vascular lesion with unknown etiopathogenesis and with definite features of imaging, histopathology, and immunohistochemistry. It was first described by Martel et al in 2004 [1], and to date, only 151 cases have been reported. Real incidence and prevalence are still unknown. We report a case of SANT of the spleen managed in our institute and we present a review of the literature
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
